

ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN

J. Carson¹, D. Haddad^{1,2}, M. Bressman¹ and Y. Fong¹

¹Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ²Institute for Biochemistry, Virchow Center for Experimental Biomedicine, University of Wuerzburg, Wuerzburg, Germany

CONTENTS

Summary	183
Introduction	183
Viral oncolysis: a historical perspective	183
Foundation – basic properties of HSV	184
Original designs – viral gene deletion	184
Augmenting efficacy through manipulation of replication, spread and host immune response	186
Arming vectors: insertion of genes encoding for anticancer proteins	188
Conclusions	190
References	190

SUMMARY

Viruses have long been considered potential anticancer treatments. Wild-type viruses have been tested as anticancer agents in clinical trials since the 1960s. The possibility of viral oncolysis as an alternate cancer therapy was transformed by the emergence of modern genetic engineering. The herpes simplex virus (HSV) family offers particular advantages for use as a viral oncolytic. The engineered vectors that make up oncolytic HSVs (oHSV) have demonstrated remarkable safety in clinical trials, with some evidence of efficacy. The past decade has seen a focus on increasing the efficacy of oncolytic vectors by adding exogenous transgenes to enhance tumor destruction. The current paper describes the various strategies for engineering HSV for increased cancer tissue specificity and efficacy. Presented are the rationale, preclinical data and clinical data where available. This is meant to illustrate a basic framework for the development of a novel therapy meant to exploit the viral life cycle for the killing of cancer.

INTRODUCTION

Over the past two decades, herpes simplex virus 1 (HSV-1) oncolytic agents have transitioned from an area of theoretical interest to a major focus in the search for novel cancer therapies. This shift from esoteric theory to clinical relevance is in large part attributable to the technological breakthroughs of genetic engineering, which have allowed investigators to design progressive generations of oncolytic HSV (oHSV) vectors, constantly improving their ability to selectively infect and treat a wide range of cancers. This article will review the evolution of these agents from casual experimentation of a century ago to various emerging strategies in contemporary vector design. Topics addressed include: 1) the historical roots of viral oncolysis; 2) the development of the first generations of modern oHSV vectors through deletion of viral genes; 3) means of engineering oHSVs to achieve increased efficiency of cancer cell infection; and 4) “arming” of oHSV vectors with transgenes that augment the agents’ efficacy through the localized expression of bioactive proteins.

VIRAL ONCOLYSIS: A HISTORICAL PERSPECTIVE

The earliest reports of what are now known to be viral diseases showing the ability to lead to cancer regression predate the discovery of viruses. In the late 19th century, reports surfaced of patients bearing significant cancers experiencing transient remissions following influenza (1-3). Levaditi et al. later demonstrated that vaccinia virus inhibited various mouse and rat tumors in 1922, labeling this phenomenon “le tumeur fait fonction d’éponge” (4).

Alice Moore became the first scientist to apply viral oncolysis to an animal model. Working with Russian Far East encephalitis virus, she showed complete regression in some cases of mouse sarcoma 180 –the first animal model to demonstrate full regression through viral oncolysis (3, 5, 6). In her work with animal modeling, Moore initiated a fundamental shift in the scientific approach to viral oncolysis –a move to generate a novel agent particularly suited for oncolysis rather than simply attempting to replicate a natural sequela to existing pathogens. Working with others at Memorial Sloan-Kettering

Correspondence: Yuman Fong, MD, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA. E-mail: fongy@mskcc.org.

Cancer Center in New York, Moore began to experiment with serial viral passaging in order to breed viral strains with improved efficacy as viral oncolytic agents, foreshadowing a modern era of oncolytic vectors genetically engineered to attain selective replication in cancer cells (3, 7, 8).

In the same year, Moore first published her application of the Russian Far East encephalitis virus to a rodent model, and Hoster et al. published the first clinical trial assessing the impact of viral infections on cancer. Twenty-one volunteers with Hodgkin's disease were inoculated with samples of sera and tissue samples from other patients noted to have developed viral hepatitis. Development of viral hepatitis in the volunteers was defined at the time of jaundice onset. Although there were obviously many significant side effects, some patients did show clinical improvement and decreased tumor size after manifesting classic stigmata of viral hepatitis (9). Shortly thereafter, a variety of small clinical trials were published around the country using various viral agents, including West Nile virus, mumps virus and Newcastle disease virus (5, 10-12). In 1956, the National Cancer Institute (NCI) conducted the first large-scale clinical study, administering wild-type adenoviruses to 30 patients with cervical cancer and achieving varying degrees of localized tumor necrosis but no significant tumor regressions or remissions (13).

While these early studies and trials were considered groundbreaking, interest in viruses as potential antineoplastic therapies was abandoned due to unimpressive and short-lived success, as well as unacceptable side effects that eventually ended the trials (3, 10). These viruses failed in that they infected and replicated in non-cancerous cells, and were unable to circumvent detection and clearance by the immune system. Limited contemporary understanding of virology, molecular biology, immunology and genetics, as well as primitive biotechniques, likely contributed to the demise of the first iteration of this field.

There was a marginal renewal of interest in viral agents as a component of therapy in the late 1970s and 1980s, with isolated animal and clinical studies. In 1974, the oncolytic potential of the mumps virus against 18 different tumor types was studied in Japan (4). Also, a 1982 report described the investigation of 16 different viruses for use in the treatment of sarcoma and Ehrlich ascites tumors in mice (14). While there were side effects from viral infection, more than half of the patients showed either complete tumor regression or decrease in tumor size. Viruses were also studied as a means to generate tumor-specific immunizations. In 1986, Hersey et al. applied a vaccinia virus oncolysate to a clinical trial of tumor vaccination in melanoma patients in Australia (15). Ultimately, though, it would not be until the emergence of modern genetic engineering in the 1990s that viral oncolysis would resurface with renewed potential as a cancer therapy.

While the potential for viruses to selectively destroy cancers has been a source of intermittent scientific interest and exploration for generations, it is over the past two decades that the modern field of viral oncolysis has emerged in earnest. What separates the modern approach to viral cancer therapeutics from earlier experimentation is the advent of genetic engineering: the ability to manipulate the vector genome to effect increased specificity and efficacy in the infection and destruction of tumor cells.

FOUNDATION – BASIC PROPERTIES OF HSV

HSV is a double-stranded DNA virus with a 152-kb circular genome encoding 84 genes, which occurs naturally in humans, with several natural advantages as a template for viral oncolysis vectors (16). Its relatively large genome allows it to accept multiple transgenes as large as 30 kb. As the HSV genome does not integrate into the host genome, it is generally nonmutagenic to its host. Finally, the existence of multiple antiviral medications with well-established safety and efficacy in the treatment of HSV infections provides a reassuring option for the hypothetical scenario in which oncolytic treatments were to lead to an unexpected pathogenic infection.

HSV-1 does have certain disadvantages as a therapeutic agent. Most intuitively, as a common human pathogen, one might expect the patient/host immune system to neutralize the vector upon administration. However, preclinical studies have found preexisting immunity to wild-type HSV-1 to have minimal if any impact on antitumor efficacy in the context of systemic delivery, and no discernable impact in locoregional treatment models (17-19).

Another theoretical concern involves the possibility of carcinogenic side effects. While the circular intracytoplasmic HSV-1 is incapable of creating host mutation through integration into host DNA, Yang et al. have shown that HSV-1 infection can indirectly lead to mutation by deregulating promoter pathways (20). Such inappropriate promoter induction could theoretically prove carcinogenic over time. While certainly worthy of addressing when considering HSV as a vehicle for the broader field of gene therapy, the short life expectancies of patients bearing the kind of advanced cancers targeted by viral oncolytic agents render such concerns moot in this particular setting.

ORIGINAL DESIGNS – VIRAL GENE DELETION

Attenuating viral replication in noncancerous cells

The initial objective in developing therapeutic agents from HSV species was to eliminate (or at least minimize) the obvious toxicity resulting from infection of noncancerous tissues. Thus, the first generations of modern (i.e., genetically engineered) oHSV vectors were created by simply deleting selected HSV-1 genes whose function was thought to be essential for infection of normal tissues but redundant for the infection of cancer cells (Table I).

Most oHSV vectors contain deletions of HSV genes necessary to supply the genetic material required for viral genome construction, as such enzymes are crucial to viral replication in relatively quiescent normal cells but nonessential in rapidly dividing cancer cells harboring a ready supply of viable genetic machinery. The first recombinant HSV strain directed against cancer, *Δ*sp_{tk}, was generated through the deletion of the *UL23* gene encoding thymidine kinase (TK) (21). TK processes nucleotides to facilitate replication of DNA. In the absence of HSV TK, HSV-1 infecting normal cells would fail to replicate at a rate sufficient to sustain infection. However, in rapidly dividing cancer cells, where a surplus of thymidine is produced by overactive native cellular replication machinery, viral replication would proceed unhindered, allowing for progressive, lytic infection. In a mouse glioma model treatment with *Δ*sp_{tk} resulted in a significant prolongation of survival as compared to wild-type mice and mice

Table I. Common oncolytic HSV vectors.

Virus (Ref.)	Mutations	Transgene	Comments
<i>Dlsptk</i> (26)	TK	–	First modern engineered oHSV vector Resistant to aciclovir
hrR3 (24, 123-126)	<i>UL39</i>	<i>lac Z</i>	Reporter gene, monitors viral replication Specifically infects dividing cancer cells
HSV1716 (18, 31, 32, 56, 127-129)	<i>RL1</i> (both copies)	–	Safety confirmed in phase I trial
NV1020 (101, 130-137)	<i>RL1</i> (one copy) <i>UL24</i> , <i>UL56</i>	HSV-2 segment	Originally developed as an HSV vaccine
G207 (133, 134, 136-146)	<i>UL39</i> <i>RL1</i> (both copies)	<i>lac Z</i>	Safety confirmed in phase I trial Effective against a broad array of tumors
G47 Δ (36, 147-154)	<i>UL39</i> <i>RL1</i> (both copies) $\alpha 47$	<i>lac Z</i>	Enhanced antitumor immune response
NV1034 (97, 99, 100)	<i>UL56</i> $\alpha 47$	GM-CSF <i>lac Z</i>	Efficacy demonstrated in SCC xenografts
NV1042 (97, 99, 155)	<i>UL56</i> $\alpha 47$	IL-12 <i>lac Z</i>	Inhibits SCC xenograft growth Elicits memory tumor immunity
NV1066 (136, 156-161)	<i>RL1</i> (one copy) $\alpha 0$, $\alpha 4$, TK	GFP	Useful in detecting small tumor deposits Inhibits esophageal tumor xenografts
OncoVEX (162, 163)	<i>RL1</i> , CP47-	GM-CSF	

GM-CSF, granulocyte–macrophage colony-stimulating factor; SCC, squamous cell carcinoma.

treated with placebo, showing only mild to moderate, self-limiting HSV encephalitis (22).

While the efficacy and selectivity of *dlsptk* established a proof of principle for the use of HSV-1 genome deletions to achieve tumor selectivity through selective attenuation, the TK deletion was ultimately problematic from the standpoint of clinical application, as it rendered the strain impervious to first-line anti-herpes medications. This resistance represented to many the loss of a crucial safety valve for clinical experimentation with viral therapies. As such, *dlsptk* and its TK deletion were abandoned in favor of HSV-1 recombinants featuring deletion of the *UL39* gene. *UL39* encodes for ICP6, a large (and critical) subunit of the ribonucleotide reductase enzyme. Ribonucleotide reductase functions to generate deoxyribonucleotides necessary for viral replication (23, 24). Deletion of *UL39* would thus be expected to improve targeting of virus to replicating cells, attenuating replication on nondividing cells and thus limiting toxicity (25). Markert et al. applied the prototypical ICP6 knockout HSV-1 strain, hrR3, to a mouse model of glioma and identified a similar therapeutic profile to that seen with *dlsptk* (26). As TK was preserved in this vector, hrR3 also demonstrated a distinct remarkable sensitivity to the common antiviral agent ganciclovir, which can theoretically be used to treat viral dissemination. *UL39* deletion remains central to many HSV-1 recombinants currently under investigation for viral oncolysis.

The next gene to attract attention during this “first generation” of oHSV vector development was *RL1* (also referred to as γ_1 34.5). At the time, the precise function of the *RL1* product, ICP34.5, was not known, although it was thought to play a crucial role in neuroviro-

lence. Subsequent research has demonstrated that in wild-type HSV-1 ICP34.5 supports sustained infection by preventing the host cell from shutting off all protein synthesis (an intracellular defense mechanism which prevents the virus from converting the host cell into a factory for virion reproduction). Upon infection by virus of a normal host cell, host RNA-dependent protein kinase (PKR) phosphorylates (and thus inactivates) the α subunit of the translation initiation factor eIF-2 α , a critical protein for host cell protein synthesis. ICP34.5 facilitates the dephosphorylation (and, as such, reactivation) of eIF-2 α (16, 27, 28). In tumor cells sensitive to *RL1* mutants, mitogen-activated protein kinase kinase (MEK) inhibits PKR phosphorylation of eIF-2 α , rendering ICP34.5 obsolete (29). The deletion of *RL1* confers an oncotropism to oHSV vectors due to MEK overexpression in a very high proportion of cancer cells. It is this overexpression that renders a cancer cell sensitive to productive infection by an *RL1* mutant (30).

The role of *RL1* in overcoming resistance to HSV infection is, in fact, not limited to neurons, but also plays an important role in infecting a wide range of cells. Thus, not only did the prototypic *RL1* mutant HSV-1716, which contains a double deletion of *RL1* and retains functional copies of both *UL39* and *TK* genes, show efficacy in a glioma model, but it was also found to be an effective oncolytic vector in a variety of non-nervous system tumors (31, 32). As such, it has become clear that the oncotropism of the HSV-1 family of oncolytic vectors is not limited by the neurotropism of the parent wild-type HSV-1 virus.

Other strains developed principally to incorporate the *RL1* mutation included HSV-G207, which contains a combined single deletion of

RL1 and single deletion of *UL39*, and MGH-1, which features a single deletion of *UL39* and double deletion of *RL1* (33, 34).

Viral deletion to augment host response

A third-generation oHSV vector, G47 Δ , was created by adding to the *UL39* and *RL1* deletions of G207 a deletion of the HSV-1 gene $\alpha 47$ (35). This gene encodes for a protein that protects the virus from host immune responses by downregulating host cell expression of major histocompatibility complex class I (MHC-I). Deleting $\alpha 47$ thus restores MHC-I and allows for tumor cells to present antigen to circulating T cells in response to infection. While this deletion might initially appear counterintuitive in that it would theoretically make the viral infection more vulnerable to host immunity, the third-generation agents exploit the host immune response to invoke a mechanism of cell killing beyond direct oncolysis. Todo et al. showed that this deletion had the intended response of increasing tumor reduction by enhancing antitumor immune response (36).

HF-10 – nature's contribution to the repertoire of oHSV vectors

One vector that continues to receive attention in both preclinical and clinical trials was not engineered at all, but rather discovered. In 2003, Takakuwa et al. reported that i.p. injection of HF-10, a spontaneously generated clone of the HSV-1 strain HF identified from their viral stock, safely and effectively treated a murine model of peritoneal carcinomatosis (37). HF-10 has since been shown to have efficacy in colorectal, pancreatic, bladder and breast cancer, as well as melanoma and sarcoma, and has been evaluated in multiple clinical trials (37-49). A mutation in *UL56* is thought to be responsible for attenuation in noncancerous cells (50). However, while experiments using HSV-2 suggest that the gene product of *UL56* plays a critical role in vesicular trafficking, its precise function in HSV-1 is unclear (51, 52). Ultimately, although several genetic rearrangements have been identified in the strain, and phenotypically it was notable for its tendency toward syncytium formation upon infection, the specific mutations and mechanisms accounting for the efficacy of HF-10 as a viral oncolytic agent remain unclear (37).

AUGMENTING EFFICACY THROUGH MANIPULATION OF REPLICATION, SPREAD AND HOST IMMUNE RESPONSE

While deletion of viral genes has proven remarkably effective in attaining selectivity of infection, a tendency towards incomplete tumor responses in clinical trials of these initial vectors highlighted the need to augment the antitumor effect of these agents (48, 53-60). This prompted the development of oHSV strains, typically derived from the basic constructs outlined above, which increased treatment efficacy through insertion (or strategic reinsertion) of genes to increase their virulence within cancer cells (without compromising the selective attenuation seen in noncancerous cells).

Viral entry: from tumor selection to tumor targeting

A key mechanism by which HSV gains access to host cells involves interactions between glycoproteins located on the virion surface and host cell receptors. These mechanisms remain significant in oncolytic virus recombinants, as well as in wild types. Huang et al. demonstrated that quantifying nectin expression in various thyroid cancer

cell lines can be used to predict sensitivity to herpesvirus oncolysis (61). Furthermore, in a murine model of squamous cell carcinoma, Yu et al. found that they were able to increase the sensitivity of established tumors to herpes oncolysis by increasing the tumor surface expression and availability of nectin through calcium depletion (62).

Beyond using cell-surface receptor expression to predict and optimize tumor sensitivity to oncolytic vectors, one can manipulate virus surface glycoproteins to increase virus-tumor cell affinity and facilitate virion entry into tumor cells. Wild-type HSV-1 bears multiple glycoproteins on its surface (most notably gB, gC and gD), which interact with host cell-surface glycosaminoglycans (most notably nectin, heparan sulfate and herpesvirus entry mediator [HVEM]) to facilitate the virion-to-cell attachment and virion penetration (16, 63). Various groups have demonstrated that by altering those surface glycoproteins, HSV strains can be engineered to show both greater affinity for a targeted cell type and weakened virulence in normal, nontargeted cells (64).

One promising method for targeting cell-surface receptors involves the application of single-chain antibodies (scFv). Menotti et al. showed that a herpes vector could be engineered to integrate a single variable fragment from a desired antibody into the herpes virion surface molecule glycoprotein D – a coreceptor which engages host cell-surface receptors to facilitate invasion – in order to target it to a molecule specific to the inserted antibody fragment (65). This technique has since been successfully applied to generate vectors showing enhanced efficacy against squamous and breast cancer by virtue of their bearing epidermal growth factor (EGF)- and HER2-targeted glycoproteins, respectively (65-67). The availability of countless antibodies to known tumor markers gives scFv-based targeting an attractive versatility, which could theoretically translate into a wide range of vectors to be selectively applied as individualized cancer therapies.

Virus replication: tumor-responsive promoters restore efficient replication within cancer cells

The remarkable safety of most oHSV vectors derives in part from the deletion of genes deemed essential to viral replication in nondividing cells. However, while these genes may not be absolutely essential to replication within dividing cancer cells, their deletion is still likely to diminish (at least somewhat) the efficiency of replication in any cell. Furthermore, although cancer cells are much more prone to active replication than noncancerous cells, at any given time some portion of cells within a tumor can be found to be in the nonreplicating state. The short duration of oHSV infections thus allows for the possibility that a subset of tumor cells may spend the entire course of infection in quiescence, and thus escape infection and lysis. This inefficiency can be overcome by reinserting the deleted genes in a manner which places them under the control of a promoter selected to activate expression of the critical gene only upon exposure to some cancer-specific trigger. Such regulators are referred to as tumor-responsive promoters.

Tumor-responsive promoters can be designed to direct oHSV vectors to tumors through several mechanisms. Such promoters may be responsive either to properties of a specific cancer cell or to a certain set of environmental conditions known to exist within tumors. Several oHSV vectors employ antigen-responsive promoters which

initiate transcription of the reinserted gene upon exposure to a specific cancer-associated antigen. Examples include vectors with antigen-driven expression of reinserted genes upon exposure to carcinoembryonic antigen (CEA), α -fetoprotein (AFP), MUC-1, Musashi and other common tumor markers (68-74) (Table II). Such promoters can be remarkably effective in restoring the potency of oHSV agents within tumor cells. However, such antigens are difficult to identify for many cancers, and the safety and efficacy of the promoter depend largely upon the specificity and consistency of the tumor-associated antigen.

A less tumor type-specific method for tumor targeting involves the use of promoters which are responsive to environmental factors unique to tumor biology at a tissue rather than cellular level. Our laboratory has demonstrated that reinserting the ribonucleotide reductase (RR)-encoding gene *UL39* into a G207 backbone such that its expression is regulated by a hypoxia-responsive promoter can enable effective herpes oncolysis of both breast and colon cancer cells previously found to be resistant to oHSV therapy, and allow for in vivo tumor reduction in a murine metastatic colon cancer model resistant to unarmed G207 (69, 75, 76). Hypoxia-responsive promoters carry the added benefit of enhancing oHSV efficacy in a tissue setting known to otherwise compromise the efficacy of conventional cancer treatments, such as chemotherapy and radiation. Furthermore, hypoxia is a tumor feature shared by many cancer types. This allows for a single vector design to be applied to multiple cancers, which can be enormously helpful in streamlining the translation to clinical applications.

Promoters can also be designed to respond to intercellular elements created by a particular genetic transformation found within the targeted tumor. Kuroda et al. demonstrated the efficacy of an oHSV vector, bM24-TE, which exploits dysregulation of the β -catenin/T-cell factor (TCF) in colorectal cancers. The *APC* mutation found in approximately 70% of colon cancers leads to constitutive expression of β -catenin, leading to intracellular levels of this protein in such

colon cancer cells being radically higher than those seen in non-cancerous cells. oHSV strain d120 (a virus attenuated by *ICP4* deletion), was modified by reinserting *ICP4* under the control of a promoter which is activated upon exposure to β -catenin/TCF. *ICP4* is an essential gene in viral replication that allows the progression from a first wave of gene expression (the so-called immediate-early or α genes) to the second wave (the expression of the so-called early or β genes). HSV-1 strains lacking a functional gene to encode for *ICP4* are thus replication-defective, i.e., they are able to infect cells upon exposure, but unable to propagate the life cycle beyond that initial phase of infection (16, 77). Applying this agent to various cancer cell lines with and without β -catenin/TCF dysregulation, they demonstrated an obvious increase in efficacy in cancer lines overexpressing β -catenin/TCF as compared to those not carrying this mutation (78).

Pan et al. recently employed the same principle to target a mutation known to play a critical role in a wide range of cancers. They created an oHSV agent, "Signal-Smart 1", which features a reinsertion of *ICP4* under the control of an Elk-responsive promoter in order to achieve selective expression in cells bearing *RAS* mutations (79) (Elk is constitutively expressed by carcinogenic *RAS* mutations). This intracellular signaling-responsive approach allows for the design of vectors tailored to specific signaling dysregulation, which could eventually be used to direct therapy to pathways known to be critical to resistance to conventional therapies. As such, these agents represent in a sense a new level of targeted therapy –an adjuvant therapy built to directly complement the principal therapy.

It should be noted that this approach of selectively engaging promoters to increase tropism can be applied inversely for the same effect. Along these lines, rather than using cancer-specific triggers to activate promoters of essential genes in cancer cells, expression of critical viral genes can be blocked in noncancerous cells. Lee et al. exploited the differential expression level of microRNA (miRNA) between normal and cancerous cells to repress the expression of the critical *ICP4* gene in normal cells by creating an oHSV vector that

Table II. Tumor-responsive promoters used to enhance oHSV efficacy.

Trigger (Ref.)	Virus	Cancer	Promoter gene	Comments
DF3/MUC1 (164)	3616	Colon, melanoma, pancreas	<i>RL1</i>	Tumor-responsive promoters applied through helper virus
Hypoxia (76)	G207 + 10xHRE	Colon to liver	<i>RR1</i>	
CEA (68)	G207	CR	<i>RR1</i>	
AFP (69)	G207+	Liver (HCC)	<i>RR1</i>	
Androgen (prostate-specific) (74)	Cgal Δ 3	Prostate	<i>ICP4</i>	
Nestin (70)	rQNestin34.5	Brain	<i>RL1</i>	Nestin has been shown to play a critical role in HSV infection across a wide range of cell types
Musashi1 (71, 72)	dvM345: G207 + M345 KeM34.5: (G207)	Glioma, NSCLC Glioma	<i>RL1</i>	–
T-cell factor (78)	bM24-TE (hrR3)	Colon, HCC	<i>ICP4</i>	Response depended on the specific mutation in <i>APC</i> (between 1 st and 2 nd 20-amino-acid repeats)
URR16 (165)	HSPV-1	Oral cancer	<i>ICP4</i>	URR16 is an oral cancer-specific marker
B-Myb (166)	Myb34.5	Colon	<i>RL1</i>	–

HCC, hepatocellular carcinoma; CR, colorectal cancer; NSCLC, non-small cell lung cancer.

incorporated complementary miRNA sequences into the *ICP4* gene such that *ICP4* expression was blocked in cells expressing these specific miRNAs. By choosing as their triggers miRNAs known to be ubiquitously expressed in normal cells (and uniquely absent in the cancer treated), the viability of an otherwise significantly virulent vector was restricted to the targeted tumor cells (80). This strategy of using ubiquitous miRNA to repress oncolytic vectors in non-cancerous cells has also been used with HSV, and is likely to be applied to other families of oncolytic viruses as well. It is particularly attractive in that in (albeit indirectly) targeting cancer cells by their failure to express a normal epigenetic regulator, miRNA-sensitive vectors inherently target dedifferentiating cells. As such, those (more differentiated) cells which prove resistant to treatment would theoretically be more likely to respond to conventional treatments than they were before viral therapy. This is not to say that there are no concerns with this approach. Most notably, the attenuation of these vectors depends upon the supposition of universal expression of the selected miRNAs in healthy cells, which is something far easier extrapolated than proven.

Viral spread: fusogenic proteins facilitate cell-to-cell vector distribution

One of the major impediments to the propagation of an oncolytic viral infection is the hostility of the extracellular environment. The large size of virions relative to typical therapeutic agents slows diffusion through the dense extracellular matrix within the tumor (81). The time spent in transit through the extracellular milieu increases the vector's exposure to immune mediators capable of sequestering virus and allows time for viral degradation (82). The efficiency of cell-to-cell spread of viral infection can be enhanced dramatically by circumventing this hostile extracellular environment, which can be accomplished through the use of fusogenic proteins.

Fusogenic glycoproteins (originally discovered in certain naturally occurring pathological viruses) cause infected cells to fuse their cell membranes with those of surrounding cells, forming a growing syncytium through which replicating virus can freely diffuse. Fu et al. constructed a vector that inserted a transgene encoding for the gibbon ape leukemia virus (GALV) fusogenic membrane glycoprotein into the vector genome. To ensure that fusogenic glycoprotein expression was limited to cancer cells, it was placed under the control of a late viral promoter, so that expression would only occur in cells which supported a full course of infection. Infection *in vitro* and *in vivo* against multiple cancer types with this virus led to improved antitumor efficacy compared to the parent (i.e., nonfusogenic) strain (83). Multiple vectors featuring transgenes encoding for fusogenic glycoproteins have since demonstrated impressive efficacy in a variety of cancer types and models, including both subcutaneous and diffuse peritoneal colon cancer, metastatic ovarian cancer and renal cell cancer (43, 84-90).

ARMING VECTORS: INSERTION OF GENES ENCODING FOR ANTICANCER PROTEINS

In addition to manipulating the infection cycle, one can also augment the anticancer efficacy of an oncolytic viral agent by using it to engage an additional anticancer mechanism. By incorporating into

the vector a transgene which expresses a protein whose function supports tumor destruction, two parallel mechanisms of tumor destruction (viral lysis and the mechanism mediated by the transgene protein) can be achieved through a single agent. Genes are thus inserted into the oHSV genome such that, upon infection of the target cell, a protein is expressed which triggers a local anticancer process. Because these "arming" genes do not interfere with the mutations used to attenuate infection in noncancerous cells, they can be inserted under the control of native viral promoters rather than engineered tumor-responsive promoters.

The first exogenous genes incorporated into oncolytic vectors were immunomodulatory cytokines employed to stimulate the host immune response to tumor cells. Ironically, the first report of an oHSV vector armed with a cytokine-coding gene described this vector as an experimental method used to probe the role of innate immunity in the response to viral oncolysis. Adreansky et al. compared the standard tumor response in a murine glioma model infected with a basic double-*RL1*-negative virus, to the tumor response seen when the same virus was armed with either IL-10 or IL-4. It was found that although IL-10 significantly limited therapeutic response, insertion of a gene coding for IL-4 led to a significant increase in tumor reduction (91). The recognition that local delivery of cytokines could augment or inhibit tumor therapy, possibly by engaging the host's own immune system against infected tumor cells, led to widespread development and investigation of vectors containing cytokine-coding genes to augment virus treatment efficacy, as well as to better understand the potential role of immunotherapy in the field of oncolytic virotherapy (92-97). Arming oHSV vectors with immunostimulatory genes allows treatment with a single agent to function through two separate treatment modalities: 1) as an infective agent that eradicates tumors through direct viral oncolysis; and 2) as an immunotherapy which re-engages and augments native anticancer immune responses. Immunotherapy is a particularly attractive modality to complement viral oncolysis, as the very presence of the virus alone naturally instigates a rich and complex immune response. The addition of a transgene which expresses an immunomodulatory protein can then be used to harness and exploit that response. As such, this approach has been widely applied in preclinical models and clinical trials. oHSVs armed with immunomodulators continue to be popular among oHSV laboratories, and continue to be studied in ongoing clinical and preclinical investigations of oHSV therapy (94, 96, 98-103).

Another way in which vectors have been armed with host genes in order to engage host systems involves the use of genes which code for antiangiogenic proteins. Increased local angiogenesis is a natural sequela of wild-type HSV infection, which appears to persist in at least some oHSV strains, which can act counter to the agent's antitumor effect. Aghi et al. demonstrated that restoring thrombospondin, an antiangiogenic protein downregulated in the setting of HSV infection, by inserting the thrombospondin gene into the G207 vector eliminated the angiogenic response to treatment, which translated into a more sustained treatment response in a murine glioma model (104). Additional examples of antiangiogenic protein genes which have been incorporated into oHSV vectors include genes coding for platelet factor 4, endostatin, endostatin-angiostatin fusion protein and double-negative fibroblast growth factor (FGF) (105-108).

A particularly interesting example of a host system engaged by armed oHSVs is the case of the metalloproteinases, proteins expressed by a variety of cells which degrade certain adhesion proteins within the extracellular matrix. Curiously, both tissue metalloproteinase-expressing genes and tissue metalloproteinase inhibitor-expressing genes have been shown to increase tumor reduction when added to oHSV vectors. Mahler et al. reasoned that since tumor-secreted metalloproteinases facilitate tumor invasion into surrounding tissues, engineering a vector to express a metalloproteinase inhibitor would enhance its antitumor effect. Applying such a vector (rQT3) to murine models of neuroblastoma and peripheral malignant nerve sheath tumors, they found that,

compared to the parent virus, treatment with the metalloproteinase inhibitor-armed vector led to increased tumor reduction and a significant antiangiogenic response (109). However, in the case of sarcoma, the dense extracellular matrix likely interferes with the cell-to-cell spread of replicating oncolytic virus. As such, Mok et al. reasoned that augmenting local expression of metalloproteinase inhibitors would improve the distribution of virus throughout the tumor. They found that transfecting sarcoma cells with genes expressing metalloproteinases did indeed increase the intratumoral distribution of virus and tumor reduction in a murine sarcoma model (110). This highlights the fact that the impact of arming an oHSV with a particular gene frequently depends upon

Table III. Clinical trials of oncolytic HSV agents.

Phase	Tumor type	Vector	Number of patients	Results		Study
				Number of patients with response ¹	Adverse events	
I	GBM	G207	21	0	None	Markert et al. (2000, USA) (60)
I	Melanoma	1716	5	1 (20%)	None	Mackie et al. (2001, UK) (59)
II	GBM	1716	12	N/A	None	Papanastassiou et al. (2002, UK) (58)
I	GBM	1716	12	2 (17%)	None	Harrow et al. (2004, UK) (57)
I	Oral SCC	1716	20	2 (10%)	No	Mace et al. (2008) (56)
I	Colorectal liver metastases	NV1020	12	2 (17%) (11/12 showed decrease in CEA levels)	10 grade 3-4 events in 3 patients	Fong et al. (55) and Kemeny et al. (54) (2006, 2009, USA)
I	Recurrent breast cancer	HF10	6	1 (15%) (some histological changes noted in tumor following treatment)	None	Teshigahara et al., Watanabe et al., Kohno et al., Nakao et al. and Kimata et al. (2004-2007, all in Japan) (45-49)
I	Pancreatic cancer		3	(0/3) Decrease in CA19-9 found in 1/3 patients		
I	Recurrent glioma	1716	9	0	No	Rampling et al. (2000, UK) (53)
I	SCC metastases	OncoVEX	8	N/A	N/A	Hu et al. (2003, UK) (167)
II	Melanoma	OncoVEX	50	13 (26%) (8 CR, 5 PR)	14 grade 3, no grade 4	Senzer et al. (2009, USA/UK) (168)
I/II	SCC, head and neck	OncoVEX (with chemo-radiation therapy)	17	13 (76%)	17 grade 3-4 AEs ²	Harrington (2009, UK) (169)
III	Metastatic melanoma (stage III and IV)	OncoVEX-GM-CSF	Estimated enrollment 430, still recruiting (tx and control with GM-CSF only)	N/A	N/A	http://www.biovex.com/oncovex.html www.clinicaltrials.gov
III	SCC, head and neck	OncoVEX-GM-CSF	Estimated enrollment	N/A	N/A	http://www.biovex.com/oncovex.html www.clinicaltrials.gov

¹Response defined as decrease in size of tumor (either on physical exam or radiological evaluation) following treatment. ²Protocol including adverse events (AEs) attributable to concurrent chemoradiation therapy. N/A, not available; CR, complete response (local); PR, partial response; GBM, glioblastoma multiforme; SCC, squamous cell cancer; CEA, carcinoembryonic antigen.

the tumor targeted by that vector. While, in contrast to tumor-selective promoters, expression may be fairly uniform across cancer types, the effect of local expression of a particular protein depends in part on the tumor biology of the cancer treated. Thus, while certain oHSVs demonstrate efficacy in a wide variety of cancers, there is likely much to be gained from specifically tailoring vectors to the disease they target.

In addition to using proteins that directly interact with host systems, oHSVs can be armed with enzymes that convert prodrugs into active forms to allow for ultralocalized chemotherapy. As modern oHSVs are typically ganciclovir-sensitive, it was initially hypothesized that systemic treatment with ganciclovir during a course of viral oncolysis would enhance cytotoxicity in infected cells. Initial experiments using ganciclovir in this manner showed that while cytotoxicity upon infection was augmented by ganciclovir treatment in some cancers, this benefit was negated by a concurrent reduction in viral propagation (111, 112). Nonetheless, the concept that the selective infection of viral oncolytic agents could be exploited to yield localized activity of systemically administered drugs was validated. Several vectors have since been engineered to express prodrugs that convert systemically administered prodrugs allowing for ultralocalized concentrations of (activated) drugs at levels previously unattainable without unacceptable systemic toxicity. Most commonly, vectors are armed with enzymes that convert prodrugs into activated forms of classic chemotherapeutic agents, such as cyclophosphamide, taxanes or alkylating agents (102, 113-118).

This approach can also be used to localize radiation therapy. Rather than prodrug conversion, HSV-facilitated localized radiotherapy utilizes cell membrane symporters to transport radioactive particles into the targeted cell. Using conventional genetic engineering techniques, multiple groups have found that transfection of the naturally occurring noradrenaline transporter gene (NAT) leads to expression of a functional symporter capable of importing radioactive iodine-131-*meta*-iodobenzylguanidine (MIBG) into the transfected cells (119-121). Quigg et al. demonstrated that arming an oHSV vector with NAT leads to the production of an NAT symporter. As such, infected cells were able to effectively concentrate ambient MIBG, leading to increased antitumor efficacy for the NAT-armed vector as compared to the unarmed control (122).

It should be emphasized that arming vectors to express prodrug-converting enzyme or radioactive particle transporters accomplishes something very different from traditional combination therapy (i.e., the simple addition of conventional chemo- or radiotherapy to a primary viral therapy). These are ultralocalizers, which expose the uninfected (i.e., virus-resistant) cells surrounding the infected cancer cells to chemo- or radiotherapeutic agents at concentrations unattainable through conventional therapeutic modalities. This represents the most promising basic aspect of armed vectors, the ability to exploit the vectors' ability to infect sensitive cells to deliver with extreme precision a second treatment specifically chosen to treat the nonsensitive cells nearby.

CONCLUSIONS

The field of oncolytic viral therapy has advanced significantly in the last decade. The improvements in viral genetic engineering have

transformed this field from one employing natural viruses to one utilizing multiply altered viruses that are more specific to cancer and less toxic to man. These recombinant viruses have also reached clinical testing in man (Table III), and have proven to be safe and tolerable in phase I and II trials. Sufficient antitumor efficacy encourages future large-scale trials and further design refinements in this novel class of cancer treatments.

DISCLOSURES

Y. Fong is a scientific advisor to Genelux Corporation. The other authors state no conflicts of interest.

REFERENCES

1. Dock, G. *Influence of complicating diseases upon leukemia*. Am J Med Sci 1904, 127: 563.
2. Kovacs, F. Wien klin Wochenschr 1893, 39: 701.
3. Sinkovics, J., Horvath, J. *New developments in the virus therapy of cancer: A historical review*. Intervirology 1993, 36(4): 193-214.
4. Levaditi, C., Nicolau, S. *Affinite du virus herpetique pour les neoplasmes epitheliaux*. Comptes Rendus Soc Biol 1922, 87: 498-500.
5. Southam, C.M., Moore, A.E. *Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus*. Cancer 1952, 5(5): 1025-34.
6. Moore, A.E. *The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180*. Cancer 1949, 2(3): 525-34.
7. Moore, A.E. *Inhibition of growth of five transplantable mouse tumors by the virus of Russian Far East encephalitis*. Cancer 1951, 4(2): 375-82.
8. Moore, A.E., O'Connor, S. *Further studies on the destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180*. Cancer 1950, 3(5): 886-90.
9. Hoster, H.A., Zanes, R.P. Jr., Von, H.E. *Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report*. Cancer Res 1949, 9(8): 473-80.
10. Vaha-Koskela, M.J., Heikkila, J.E., Hinkkanen, A.E. *Oncolytic viruses in cancer therapy*. Cancer Lett 2007, 254(2): 178-216.
11. Asada, T. *Treatment of human cancer with mumps virus*. Cancer 1974, 34(6): 1907-28.
12. Okuno, Y., Asada, T., Yamanishi, K. et al. *Studies on the use of mumps virus for treatment of human cancer*. Biken J 1978, 21(2): 37-49.
13. Smith, R.R., Huebner, R.J., Rowe, W.P., Schatten, W.E., Thomas, L.B. *Studies on the use of viruses in the treatment of carcinoma of the cervix*. Cancer 1956, 9(6): 1211-8.
14. Mettler, N.E., Clarke, D.H., Casals, J. *Virus inoculation in mice bearing Ehrlich ascitic tumors: Antigen production and tumor regression*. Infect Immun 1982, 37(1): 23-7.
15. Hersey, P., Coates, A.S., McCarthy, W.H. et al. *Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial*. J Clin Oncol 2002, 20(20): 4181-90.
16. Roizman, B., Knipe, D., Whitley, R. *Herpes simplex viruses*. In: Fields Virology, 5th Ed. D.M. Knipe, P. Howley (Eds). Philadelphia: Lippincott Williams & Wilkins, 2007, 2501-602.
17. Delman, K., Bennett, J.J., Zager, J.S. et al. *Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy*. Hum Gene Ther 2000, 11(18): 2465-72.

18. Lambright, E.S., Kang, E.H., Force, S. et al. *Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.* Mol Ther 2000, 2(4): 387-93.
19. Chahnavi, A., Rabkin, S., Todo, T., Sundaresan, P., Martuza, R. *Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.* Gene Ther 1999, 6(10): 1751-8.
20. Yang, C.T., Song, J., Bu, X. et al. *Herpes simplex virus type-1 infection upregulates cellular promoters and telomerase activity in both tumor and nontumor human cells.* Gene Ther 2003, 10(17): 1494-502.
21. Coen, D.M., Kosz-Vnenchak, M., Jacobson, J.G. et al. *Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.* Proc Natl Acad Sci U S A 1989, 86(12): 4736-40.
22. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L., Coen, D.M. *Experimental therapy of human glioma by means of a genetically engineered virus mutant.* Science 1991, 252(5007): 854-6.
23. Goldstein, D.J., Weller, S.K. *Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant.* J Virol 1988, 62(1): 196-205.
24. Goldstein, D.J., Weller, S.K. *Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant.* Virology 1988, 166(1): 41-51.
25. Jacobson, J.G., Leib, D.A., Goldstein, D.J. et al. *A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.* Virology 1989, 173(1): 276-83.
26. Markert, J.M., Malick, A., Coen, D.M., Martuza, R.L. *Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir.* Neurosurgery 1993, 32(4): 597-603.
27. He, B., Gross, M., Roizman, B. *The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.* Proc Natl Acad Sci U S A 1997, 94(3): 843-8.
28. He, B., Gross, M., Roizman, B. *The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells.* J Biol Chem 1998, 273(33): 20737-43.
29. Smith, K.D., Mezhr, J.J., Bickenbach, K. et al. *Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by deltagamma(1)34.5 mutants of herpes simplex virus 1.* J Virol 2006, 80(3): 1110-20.
30. Veerapong, J., Bickenbach, K.A., Shao, M.Y. et al. *Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.* Cancer Res 2007, 67(17): 8301-6.
31. Detta, A., Harland, J., Hanif, I., Brown, S.M., Cruickshank, G. *Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours.* J Gene Med 2003, 5(8): 681-9.
32. Benencia, F., Courreges, M.C., Conejo-Garcia, J.R. et al. *HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.* Mol Ther 2005, 12(5): 789-802.
33. Yazaki, T., Manz, H.J., Rabkin, S.D., Martuza, R.L. *Treatment of human malignant meningiomas by G207, a replication-competent multmutated herpes simplex virus 1.* Cancer Res 1995, 55(21): 4752-6.
34. Kramm, C.M., Chase, M., Herrlinger, U. et al. *Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.* Hum Gene Ther 1997, 8(17): 2057-68.
35. Mavromara-Nazos, P., Ackermann, M., Roizman, B. *Construction and properties of a viable herpes simplex virus 1 recombinant lacking coding sequences of the alpha 47 gene.* J Virol 1986, 60(2): 807-12.
36. Todo, T., Martuza, R.L., Rabkin, S.D., Johnson, P.A. *Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.* Proc Natl Acad Sci U S A 2001, 98(11): 6396-401.
37. Takakuwa, H., Goshima, F., Nozawa, N. et al. *Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice.* Arch Virol 2003, 148(4): 813-25.
38. Ogawa, F., Takaoka, H., Iwai, S., Aota, K., Yura, Y. *Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma.* Anticancer Res 2008, 28(6A): 3637-45.
39. Luo, C., Mori, I., Goshima, F. et al. *Replication-competent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment.* J Gene Med 2007, 9(10): 875-83.
40. Fujimoto, Y., Mizuno, T., Sugiura, S. et al. *Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.* Acta Otolaryngol 2006, 126(10): 1115-7.
41. Kohno, S., Luo, C., Goshima, F., Nishiyama, Y., Sata, T., Ono, Y. *Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.* Urology 2005, 66(5): 1116-21.
42. Sugiura, S., Goshima, F., Takakuwa, H., Sata, T., Nakashima, T., Nishiyama, Y. *Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.* Otolaryngol Head Neck Surg 2004, 130(4): 470-8.
43. Kimata, H., Takakuwa, H., Goshima, F. et al. *Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.* Hepatogastroenterology 2003, 50(52): 961-6.
44. Nawa, A., Luo, C., Zhang, L. et al. *Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.* Curr Gene Ther 2008, 8(3): 208-21.
45. Teshigahara, O., Goshima, F., Takao, K. et al. *Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.* J Surg Oncol 2004, 85(1): 42-7.
46. Watanabe, D., Goshima, F., Mori, I., Tamada, Y., Matsumoto, Y., Nishiyama, Y. *Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.* J Dermatol Sci 2008, 50(3): 185-96.
47. Kohno, S.I., Luo, C., Nawa, A. et al. *Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.* Cancer Gene Ther 2007, 14(11): 918-26.
48. Nakao, A., Takeda, S., Shimoyama, S. et al. *Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.* Curr Cancer Drug Targets 2007, 7(2): 169-74.
49. Kimata, H., Imai, T., Kikumori, T. et al. *Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.* Ann Surg Oncol 2006, 13(8): 1078-84.
50. Berkowitz, C., Moyal, M., Rosen-Wolff, A., Darai, G., Becker, Y. *Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice.* Arch Virol 1994, 134(1-2): 73-83.
51. Ushijima, Y., Goshima, F., Kimura, H., Nishiyama, Y. *Herpes simplex virus type 2 tegument protein UL56 relocates ubiquitin ligase Nedd4 and has a role in transport and/or release of virions.* Virol J 2009, 6: 168.

52. Koshizuka, T., Goshima, F., Takakuwa, H. et al. *Identification and characterization of the UL56 gene product of herpes simplex virus type 2*. J Virol 2002, 76(13): 6718-28.
53. Rampling, R., Cruickshank, G., Papanastassiou, V. et al. *Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma*. Gene Ther 2000, 7(10): 859-66.
54. Kemeny, N., Brown, K., Covey, A. et al. *Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver*. Hum Gene Ther 2006, 17(12): 1214-24.
55. Fong, Y., Kim, T., Bhargava, A. et al. *A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer*. Mol Ther 2009, 17(2): 389-94.
56. Mace, A.T., Ganly, I., Soutar, D.S., Brown, S.M. *Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma*. Head Neck 2008, 30(8): 1045-51.
57. Harrow, S., Papanastassiou, V., Harland, J. et al. *HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival*. Gene Ther 2004, 11(22): 1648-58.
58. Papanastassiou, V., Rampling, R., Fraser, M. et al. *The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study*. Gene Ther 2002, 9(6): 398-406.
59. MacKie, R.M., Stewart, B., Brown, S.M. *Intralesional injection of herpes simplex virus 1716 in metastatic melanoma*. Lancet 2001, 357(9255): 525-6.
60. Markert, J.M., Medlock, M.D., Rabkin, S.D. et al. *Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial*. Gene Ther 2000, 7(10): 867-74.
61. Huang, Y.Y., Yu, Z., Lin, S.F., Li, S., Fong, Y., Wong, R.J. *Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy*. J Clin Endocrinol Metab 2007, 92(5): 1965-70.
62. Yu, Z., Li, S., Huang, Y.Y., Fong, Y., Wong, R.J. *Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma*. Cancer Gene Ther 2007, 14(8): 738-47.
63. Laquerre, S., Argnani, R., Anderson, D.B., Zucchini, S., Manservigi, R., Glorioso, J.C. *Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread*. J Virol 1998, 72(7): 6119-30.
64. Zhou, G., Ye, G.J., Debinski, W., Roizman, B. *Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction*. Proc Natl Acad Sci U S A 2002, 99(23): 15124-9.
65. Menotti, L., Cerretani, A., Campadelli-Fiume, G. *A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors*. J Virol 2006, 80(11): 5531-9.
66. Conner, J., Braidwood, L., Brown, S.M. *A strategy for systemic delivery of the oncolytic herpes virus HSV1716: Redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein*. Gene Ther 2008, 15(24): 1579-92.
67. Menotti, L., Nicoletti, G., Gatta, V. et al. *Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells*. Proc Natl Acad Sci U S A 2009, 106(22): 9039-44.
68. Reinblatt, M., Pin, R.H., Fong, Y. *Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer*. Surgery 2004, 136(3): 579-84.
69. Pin, R.H., Reinblatt, M., Fong, Y. *Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma*. Ann Surg 2004, 240(4): 659-65.
70. Kambara, H., Okano, H., Chiocca, E.A., Saeki, Y. *An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor*. Cancer Res 2005, 65(7): 2832-9.
71. Kanai, R., Tomita, H., Shinoda, A. et al. *Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence*. Gene Ther 2006, 13(2): 106-16.
72. Kanai, R., Eguchi, K., Takahashi, M. et al. *Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer—Expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy*. J Gene Med 2006, 8(11): 1329-40.
73. Kasuya, H., Pawlik, T.M., Mullen, J.T. et al. *Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen*. Cancer Res 2004, 64(7): 2561-7.
74. Lee, C.Y., Bu, L.X., Rennie, P.S., Jia, W.W. *An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells*. Cancer Gene Ther 2007, 14(7): 652-60.
75. Chun, Y.S., Adusumilli, P.S., Fong, Y. *Employing tumor hypoxia for oncolytic therapy in breast cancer*. J Mammary Gland Biol Neoplasia 2005, 10(4): 311-8.
76. Reinblatt, M., Pin, R.H., Federoff, H.J., Fong, Y. *Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases*. Ann Surg 2004, 239(6): 892-9.
77. DeLuca, N.A., McCarthy, A.M., Schaffer, P.A. *Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4*. J Virol 1985, 56(2): 558-70.
78. Kuroda, T., Rabkin, S.D., Martuza, R.L. *Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector*. Cancer Res 2006, 66(20): 10127-35.
79. Pan, W., Bodempudi, V., Esfandyari, T., Farassati, F. *Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1*. PLoS ONE 2009, 4(8): e6514.
80. Lee, C.Y., Rennie, P.S., Jia, W.W. *MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells*. Clin Cancer Res 2009, 15(16): 5126-35.
81. Jain, R.K. *The next frontier of molecular medicine: Delivery of therapeutics*. Nat Med 1998, 4(6): 655-7.
82. Mok, W., Stylianopoulos, T., Boucher, Y., Jain, R.K. *Mathematical modeling of herpes simplex virus distribution in solid tumors: Implications for cancer gene therapy*. Clin Cancer Res 2009, 15(7): 2352-60.
83. Fu, X., Tao, L., Jin, A., Vile, R., Brenner, M.K., Zhang, X. *Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect*. Mol Ther 2003, 7(6): 748-54.
84. Hoffmann, D., Bayer, W., Wildner, O. *Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis*. Hum Gene Ther 2007, 18(5): 435-50.
85. Nakamori, M., Fu, X., Meng, F. et al. *Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms*. Clin Cancer Res 2003, 9(7): 2727-33.
86. Nakamori, M., Fu, X., Rousseau, R., Chen, S.Y., Zhang, X. *Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity*. Mol Ther 2004, 9(5): 658-65.

87. Nakamori, M., Fu, X., Pettaway, C.A., Zhang, X. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. *Prostate* 2004, 60(1): 53-60.
88. Israyelyan, A.H., Melancon, J.M., Lomax, L.G. et al. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells. *Hum Gene Ther* 2007, 18(5): 457-73.
89. Fu, X., Nakamori, M., Tao, L., Amato, R., Zhang, X. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. *Int J Oncol* 2007, 30(6): 1561-7.
90. Israyelyan, A., Chouljenko, V.N., Baghian, A., David, A.T., Kearney, M.T., Kousoulas, K.G. Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. *Viro J* 2008, 5: 68.
91. Andreansky, S., He, B., van Cott, J. et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. *Gene Ther* 1998, 5(1): 121-30.
92. Bennett, J.J., Malhotra, S., Wong, R.J. et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. *Ann Surg* 2001, 233(6): 819-26.
93. Jarnagin, W.R., Zager, J.S., Klimstra, D. et al. Neoadjuvant treatment of hepatic malignancy: An oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. *Cancer Gene Ther* 2003, 10(3): 215-23.
94. Varghese, S., Rabkin, S.D., Liu, R., Nielsen, P.G., Ipe, T., Martuza, R.L. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. *Cancer Gene Ther* 2006, 13(3): 253-65.
95. Han, Z.Q., Assenberg, M., Liu, B.L. et al. Development of a second-generation oncolytic herpes simplex virus expressing TNFalpha for cancer therapy. *J Gene Med* 2007, 9(2): 99-106.
96. Wong, R.J., Chan, M.K., Yu, Z. et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. *Clin Cancer Res* 2004, 10(1, Pt. 1): 251-9.
97. Wong, R.J., Patel, S.G., Kim, S. et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. *Hum Gene Ther* 2001, 12(3): 253-65.
98. Todo, T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. *Cell Adh Migr* 2008, 2(3): 208-13.
99. DeRubertis, B.G., Stiles, B.M., Bhargava, A. et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. *Cancer Gene Ther* 2007, 14(6): 590-7.
100. Malhotra, S., Kim, T., Zager, J. et al. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. *Surgery* 2007, 141(4): 520-9.
101. Varghese, S., Rabkin, S.D., Nielsen, P.G., Wang, W., Martuza, R.L. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. *Clin Cancer Res* 2006, 12(9): 2919-27.
102. Simpson, G.R., Han, Z., Liu, B., Wang, Y., Campbell, G., Coffin, R.S. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. *Cancer Res* 2006, 66(9): 4835-42.
103. Coffin, R.S., Liu, B., Ziquan, H. et al. OncoVEX: A family of oncolytic herpes simplex viruses optimised for therapeutic use. *Mol Ther* 2006, 13(Suppl. 1): Abst 166.
104. Aghi, M., Rabkin, S.D., Martuza, R.L. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. *Cancer Res* 2007, 67(2): 440-4.
105. Liu, T.C., Zhang, T., Fukuhara, H. et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. *Mol Ther* 2006, 14(6): 789-97.
106. Mullen, J.T., Donahue, J.M., Chandrasekhar, S. et al. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. *Cancer* 2004, 101(4): 869-77.
107. Yang, C.T., Lin, Y.C., Lin, C.L. et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. *Anticancer Res* 2005, 25(3B): 2049-54.
108. Liu, T.C., Zhang, T., Fukuhara, H. et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. *Clin Cancer Res* 2006, 12(22): 6791-9.
109. Mahller, Y.Y., Vaikunth, S.S., Ripberger, M.C. et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. *Cancer Res* 2008, 68(4): 1170-9.
110. Mok, W., Boucher, Y., Jain, R.K. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. *Cancer Res* 2007, 67(22): 10664-8.
111. Todo, T., Rabkin, S.D., Martuza, R.L. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. *Cancer Gene Ther* 2000, 7(6): 939-46.
112. Pawlik, T.M., Nakamura, H., Mullen, J.T. et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. *Cancer* 2002, 95(5): 1171-81.
113. Tyminski, E., Leroy, S., Terada, K. et al. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. *Cancer Res* 2005, 65(15): 6850-7.
114. Currier, M.A., Gillespie, R.A., Sawtell, N.M. et al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. *Mol Ther* 2008, 16(5): 879-85.
115. Braidwood, L., Dunn, P.D., Hardy, S., Evans, T.R., Brown, S.M. Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. *Anticancer Res* 2009, 29(6): 2159-66.
116. Ishida, D., Nawa, A., Tanino, T. et al. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus. *Cancer Lett* 2010, 288(1): 17-27.
117. Nawa, A., Nozawa, N., Goshima, F. et al. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type 1 mutant in a mouse model. *Gynecol Oncol* 2003, 91(1): 81-8.
118. Watanabe, I., Kasuya, H., Nomura, N. et al. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. *Cancer Chemother Pharmacol* 2008, 61(5): 875-82.
119. Mandell, R.B., Mandell, L.Z., Link, C.J. Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. *Cancer Res* 1999, 59(3): 661-8.
120. Boyd, M., Cunningham, S.H., Brown, M.M., Mairs, R.J., Wheldon, T.E. Noradrenaline transporter gene transfer for radiation cell kill by ¹³¹I meta-iodobenzylguanidine. *Gene Ther* 1999, 6(6): 1147-52.
121. Boyd, M., Mairs, R.J., Cunningham, S.H. et al. A gene therapy/targeted radiotherapy strategy for radiation cell kill by. *J Gene Med* 2001, 3(2): 165-72.

122. Quigg, M., Mairs, R.J., Brown, S.M. et al. *Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.* Med Chem 2005, 1(5): 423-9.
123. Carroll, N.M., Chiocca, E.A., Takahashi, K., Tanabe, K.K. *Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.* Ann Surg 1996, 224(3): 323-9; discussion 329-30.
124. Kulu, Y., Dorfman, J.D., Kuruppu, D. et al. *Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice.* Cancer Gene Ther 2009, 16(4): 291-7.
125. Mahller, Y.Y., Rangwala, F., Ratner, N., Cripe, T.P. *Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.* Pediatr Blood Cancer 2006, 46(7): 745-54.
126. Cullinan, A.E., Lindstrom, M.J., Sabet, S., Albert, D.M., Brandt, C.R. *Evaluation of the antitumor effects of herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.* Curr Eye Res 2004, 29(2-3): 167-72.
127. Benencia, F., Courreges, M.C., Conejo-Garcia, J.R. et al. *Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.* Hum Gene Ther 2005, 16(6): 765-78.
128. Kesari, S., Randazzo, B.P., Valyi-Nagy, T. et al. *Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.* Lab Invest 1995, 73(5): 636-48.
129. Randazzo, B.P., Bhat, M.G., Kesari, S., Fraser, N.W., Brown, S.M. *Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.* J Invest Dermatol 1997, 108(6): 933-7.
130. Kelly, K.J., Wong, J., Fong, Y. *Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy.* Expert Opin Investig Drugs 2008, 17(7): 1105-13.
131. Neville, R.W., Stewart, G.A., Sutton, P.M., Taghizadeh, A., Trethewey, J. *Anti-insulin serum, plasma insulin, and the hypoglycaemia of total pancreatectomy and partial hepatectomy in the rat.* Br J Exp Pathol 1971, 52: 1-6.
132. Delman, K.A., Zager, J.S., Bhargava, A. et al. *Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy.* Hepatology 2004, 39(6): 1525-32.
133. Bennett, J.J., Delman, K.A., Burt, B.M. et al. *Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.* Cancer Gene Ther 2002, 9(11): 935-45.
134. Cozzi, P.J., Burke, P.B., Bhargava, A. et al. *Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.* Prostate 2002, 53(2): 95-100.
135. Wong, R.J., Kim, S.H., Joe, J.K., Shah, J.P., Johnson, P.A., Fong, Y. *Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.* J Am Coll Surg 2001, 193(1): 12-21.
136. Kelsen, D., Karpeh, M., Schwartz, G. et al. *Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus Intravenous fluorouracil.* J Clin Oncol 1999, 14: 1818-28.
137. McAuliffe, P.F., Jamagin, W.R., Johnson, P., Delman, K.A., Federoff, H., Fong, Y. *Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses.* J Gastrointest Surg 2000, 4(6): 580-8.
138. Zuber-Jerger, I., Geissler, M., Spangenberg, H.C., Mohr, L., Weizsacker, F., Blum, H.E. *Local ablation of malignant lesions of the liver - Potential applications and limitations of the different methods.* Zeit Gastroenterol 2004, 42(1): 31-8.
139. Song, T.J., Eisenberg, D.P., Adusumilli, P.S., Hezel, M., Fong, Y. *Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.* J Gastrointest Surg 2006, 10(4): 532-42.
140. Cinatl, J. Jr., Michaelis, M., Driever, P.H. et al. *Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.* Neoplasia 2004, 6(6): 725-35.
141. Cozzi, P.J., Malhotra, S., McAuliffe, P. et al. *Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and NV1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model.* FASEB J 2001, 15(7): 1306-8.
142. Oyama, M., Ohigashi, T., Hoshi, M., Murai, M., Uyemura, K., Yazaki, T. *Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.* Jpn J Cancer Res 2000, 91(12): 1339-44.
143. Soudon, P., Stijns, M., Tremoureaux-Wattiez, M., Vliers, A. *Precocity of pulmonary vascular obstruction of Down's syndrome.* Eur J Cardiol 1975, 2(4): 473-6.
144. Coukos, G., Makrigiannakis, A., Montas, S. et al. *Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.* Cancer Gene Ther 2000, 7(2): 275-83.
145. Schweizer, W., Tanner, S., Baer, H.U., Huber, A., Berchtold, R., Blumgart, L.H. *[Diagnosis and therapy of liver injuries in the polytraumatized patient].* Helv Chir Acta 1989, 55: 597-612.
146. Kooby, D.A., Carew, J.F., Halterman, M.W. et al. *Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).* FASEB J 1999, 13(11): 1325-34.
147. Passer, B.J., Wu, C.L., Wu, S., Rabkin, S.D., Martuza, R.L. *Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.* Gene Ther 2009, 16(12): 1477-82.
148. Todo, T. *Oncolytic virus therapy using genetically engineered herpes simplex viruses.* Front Biosci 2008, 13: 2060-4.
149. Prabhakar, S., Messerli, S.M., Stemmer-Rachamimov, A.O. et al. *Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.* Cancer Gene Ther 2007, 14(5): 460-7.
150. Fukuhara, H., Martuza, R.L., Rabkin, S.D., Ito, Y., Todo, T. *Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.* Clin Cancer Res 2005, 11(21): 7886-90.
151. Liu, R., Martuza, R.L., Rabkin, S.D. *Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.* Gene Ther 2005, 12(8): 647-54.
152. Liu, R., Varghese, S., Rabkin, S.D. *Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.* Cancer Res 2005, 65(4): 1532-40.
153. Kolodkin-Gal, D., Edden, Y., Hartshtark, Z. et al. *Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.* Gene Ther 2009, 16(7): 905-15.
154. Nicolo, M., Chiocca, E.A. *Marker gene transfer and oncolysis of human Y79 retinoblastoma cells mediated by herpes simplex virus mutants.* Ophthalmic Res 1998, 30(1): 30-6.
155. James, R.D., Wilkinson, P.M., Belli, F., Welch, R., Cowan, R. *Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: Preliminary results.* Acta Hematol 1992, 87(Suppl.): 12-5.
156. Adusumilli, P.S., Chan, M.K., Hezel, M. et al. *Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma.* Ann Surg Oncol 2007, 14(1): 258-69.

157. Stiles, B.M., Adusumilli, P.S., Stanziale, S.F. et al. *Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer*. *Int J Oncol* 2006, 28(6): 1429-39.
158. Adusumilli, P.S., Stiles, B.M., Chan, M.K. et al. *Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer*. *Ann Thorac Surg* 2005, 80(2): 409-16.
159. Currier, M.A., Adams, L.C., Mahller, Y.Y., Cripe, T.P. *Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses*. *Cancer Gene Ther* 2005, 12(4): 407-16.
160. Stanziale, S.F., Petrowsky, H., Adusumilli, P.S., Ben Porat, L., Gonen, M., Fong, Y. *Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: A potential target to increase anti-cancer activity*. *Clin Cancer Res* 2004, 10(9): 3225-32.
161. Cameron, C., Hota-Mitchell, S., Chen, L. et al. *The complete DNA sequence of myxoma virus*. *Virology* 1999, 264(2): 298-318.
162. Toda, M., Martuza, R.L., Rabkin, S.D. *Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor*. *Mol Ther* 2000, 2(4): 324-9.
163. Liu, B.L., Robinson, M., Han, Z.Q. et al. *ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties*. *Gene Ther* 2003, 10(4): 292-303.
164. Weiss, G.R., Garnick, M.B., Osteen, R.T. et al. *Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump*. *J Clin Oncol* 1983, 1(5): 337-44.
165. Griffith, C., Noonan, S., Lou, E., Shillito, E.J. *An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16*. *Cancer Gene Ther* 2007, 14(12): 985-93.
166. Nakamura, H., Kasuya, H., Mullen, J.T. et al. *Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5*. *J Clin Invest* 2002, 109(7): 871-82.
167. Hu, J.C., Shorrock, J., Steiner, C., Love, R., Coffin, C. *A phase I clinical trial with OncoVEX (GM-CSF)*. *Proc Am Soc Clin Oncol (ASCO)* 2003, 22: Abst 742.
168. Senzer, N.N., Kaufman, H.L., Amatruda, T. et al. *Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma*. *J Clin Oncol* 2009, 27(34): 5763-71.
169. Harrington, K., Hingorani, M., Tanay, M. et al. *Phase I/II dose escalation study of OncoVexGM-CSF and chemoradiotherapy in untreated stage III/IV squamous cell cancer of the head and neck (SCCHN)*. *J Clin Oncol* [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 6018.